In accordance with 35 USC § 287(a), Shire provides United States Patent information concerning its products on this website. For each of the products listed below, the product is patented under, made under, or used under one or more of the patents listed with the product name.
The patent information displayed on this page is believed to be accurate as of the most recent update of the page, but should not be considered exhaustive. In particular, the omission of a particular patent from a product’s entry on this page is not a representation or admission by Shire that that patent does not cover the product; nor does the absence of any listing on this page for a specific Shire product constitute a representation or admission by Shire that that product is unpatented. In addition, although Shire has attempted to keep the information on this page reasonably current, certain patents listed on this page may have expired since the page was last updated.
Please note that some of the products marketed below were sold under the name of Baxalta Incorporated, and its subsidiaries. These products may be marketed currently by Shire with labeling that references a subsidiary of Baxalta Incorporated as the manufacturer and/or distributor, and that reference the patent-marking webpage www.baxtalta.com/productpatents.
Please find the product name below to view associated United States Patents.
ADVATE® (Antihemophilic Factor [Recombinant]) and BAXJECT III® Reconstitution System
Patented and/or made under U.S. Patent Numbers: 5,733,873; 5,854,021; 5,919,766; 5,955,448; 6,100,061; 6,313,102; 6,475,725; 6,555,391; 6,586,573; 6,649,386; 6,936,441; 7,087,723; 7,094,574; 7,247,707; 7,253,262; 7,381,796; and 8,545,476.
HYQVIA® (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase)
Patented under U.S. Patent Number 7,767,429, under license from Halozyme, Inc., a wholly owned subsidiary of Halozyme Therapeutics, Inc.
MYDAYIS™ (Mixed Salts of a Single-entity Amphetamine Product)
Patented under and/or used under U.S. Patent Numbers: RE 41148; RE 42096; 6,913,768; 8,846,100 and 9,173,857.
XIIDRA® (Lifitegrast Ophthalmic Solution) 5%
Patented under, used under, and/or made under U.S. Patent Numbers: 7,314,938; 7,745,460; 7,790,743; 7,928,122; 8,084,047; 8,168,655; 8,367,701; 8,592,450; 8,927,574; 9,085,553; 9,216,174; 9,353,088 and 9,447,077.